New Delhi, March 20 (IANS) Union Minister of State (independent charge) for Science and Technology Jitendra Singh met with Microsoft co-founder and philanthropist Bill Gates to discuss collaborations on biotech startups and health innovations in India, Ministry of Science & Technology said on Thursday.
The discussions with Gates, currently on an India visit, covered advancement in gene therapy, vaccine innovation, biotechnology manufacturing, and India’s evolving startup ecosystem.
“Under Prime Minister Narendra Modi, India has witnessed a surge in biotech innovations, supported by policies like Bio E3–biotechnology for the economy, employment, and environment,” said Singh.
He also highlighted the growing role of private players and startups in driving India’s bio-revolution, with structured mechanisms like the Biotechnology Industry Research Assistance Council (BIRAC) fostering collaborations.
Lauding India’s biotech advancements, Gates also “acknowledge its leadership in vaccine development, including partnerships that led to the HPV and Covid-19 vaccines”, the ministry said.
“India’s research ecosystem presents immense opportunities for global health breakthroughs,” Gates said, while also expressing interest in supporting India’s efforts in tackling diseases like tuberculosis and malaria.
Further, Singh said that more than 10,000 startups are now operating in the biotechnology sector. Of these “70 per cent are focused on medical and health biotech, with the rest contributing to agriculture, environment, and industrial biotechnology”.
He underlined the government’s commitment to scaling up these innovations, with increased funding and policy measures aimed at enabling faster commercialisation.
Gates and Singh also explored opportunities for direct investments in Indian biotech startups through Gift City — a financial hub designed to facilitate global investments.
Gates noted that while the Bill and Melinda Gates Foundation primarily operates in the philanthropic space, leveraging new financial structures could enable direct investments into promising Indian startups.
Even as India accelerates its biotechnology growth, Singh reaffirmed the government’s focus on fostering public-private partnerships to ensure that the sector continues to thrive.
“With increased research and development funding and international collaborations, India is poised to become a global hub for biotechnology innovation,” Singh said.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
